The predictive model constructed using four genes involved in macrophages and cancer cells, namely POSTN, CHI3L1, SAA1, and MMP9, holds promise in distinguishing high inflammation-hypoxia-immunosuppression microenvironment signatures and helps optimize trametinib selection for glioma treatment. Here, MMP9 is linked to glioma.